Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2022-03-31 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Correction Report). It details changes to previously reported stock option grants due to employee departures and updates the total number of options granted. This type of disclosure regarding changes to capital structure and employee compensation instruments falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the Korea Exchange/Financial Services Commission that does not fit into the more specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance).
2022-03-31 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is an amendment (정정신고) to a previous filing. It details changes to stock option grants, including the number of shares and the list of recipients. In the context of financial filings, reports regarding stock options, equity compensation, and capital changes that do not fit into specific categories like 'Director's Dealing' or 'Share Issue' are classified as general regulatory filings.
2022-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Annual General Meeting (AGM), detailing the approval of financial statements, board appointments, and other resolutions passed during the meeting. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-03-30 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment and reappointment of outside directors (사외이사). It details the names, backgrounds, and terms of the directors appointed during the company's 6th Annual General Meeting. This falls under the category of Board/Management Information (MANG) as it specifically concerns changes and appointments within the company's board structure.
2022-03-30 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure is a standard regulatory requirement for listed companies in Korea regarding capital structure and compensation-related equity changes. Since it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), and it is a mandatory regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2022-03-30 Korean
투자판단관련주요경영사항(이중항체 항암제 ABL001의 제1b상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) titled 'Investment Judgment Related Major Management Matters'. It details the results of a Phase 1b clinical trial for the drug ABL001. In the context of financial filings, clinical trial results and regulatory updates regarding drug development are classified as 'Regulatory Filings' (RNS) when they do not fit into specific categories like Earnings Releases or Annual Reports. It is a direct disclosure of material information to the market.
2022-03-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.